Kindred Biosciences, Inc. Logo

Kindred Biosciences, Inc.

KIN

(0.5)
Stock Price

9,25 USD

-24.66% ROA

-31.62% ROE

-15.38x PER

Market Cap.

0,00 USD

30.29% DER

0% Yield

-56.03% NPM

Kindred Biosciences, Inc. Stock Analysis

Kindred Biosciences, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Kindred Biosciences, Inc. Fundamental Stock Analysis
# Analysis Rating
1 DER

The stock has a minimal amount of debt (42%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

2 ROE

The stock's ROE indicates a negative return (-31.62%) on shareholders' equity, suggesting poor financial performance.

3 ROA

The stock's ROA (-24.66%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

4 PBV

The stock's high Price-to-Book Value (P/BV) ratio (5.39x) suggests it's overvalued, potentially making it an expensive investment.

5 Revenue Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

6 Net Profit Growth

This company's net profit has remained flat over the past five years, suggesting a lack of growth and making it a less attractive investment opportunity.

7 Assets Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

8 Graham Number

The company's Graham number indicates that it is overvalued compared to its stock price, suggesting a potentially unfavorable investment opportunity.

9 Dividend Growth

The company's dividend growth has been flat for the past three years, raising concerns for potential investors seeking reliable returns.

10 Dividend

The company's lack of dividends in the past three years may concern investors seeking regular income.

11 Buffet Intrinsic Value

The company's stock appears overvalued (-17) by Warren Buffett's formula, suggesting a less favorable investment opportunity as its market price exceeds its estimated intrinsic value.

Kindred Biosciences, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Kindred Biosciences, Inc. Technical Stock Analysis
# Analysis Recommendation

Kindred Biosciences, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Kindred Biosciences, Inc. Revenue
Year Revenue Growth
2012 0
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 1.966.000 100%
2019 4.256.000 53.81%
2020 42.164.000 89.91%
2021 14.148.000 -198.02%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Kindred Biosciences, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
2012 75.000
2013 3.140.606 97.61%
2014 18.694.000 83.2%
2015 19.412.000 3.7%
2016 13.861.000 -40.05%
2017 17.665.000 21.53%
2018 26.399.000 33.08%
2019 28.310.000 6.75%
2020 31.281.000 9.5%
2021 22.292.000 -40.32%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Kindred Biosciences, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
2012 45.000
2013 1.078.687 95.83%
2014 8.539.000 87.37%
2015 6.858.000 -24.51%
2016 6.840.000 -0.26%
2017 11.904.000 42.54%
2018 22.079.000 46.08%
2019 37.926.000 41.78%
2020 21.979.000 -72.56%
2021 23.476.000 6.38%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Kindred Biosciences, Inc. EBITDA
Year EBITDA Growth
2012 -120.000
2013 -4.210.183 97.15%
2014 -27.081.000 84.45%
2015 -26.984.000 -0.36%
2016 -22.344.000 -20.77%
2017 -30.404.000 26.51%
2018 -48.885.000 37.81%
2019 -58.850.000 16.93%
2020 -15.292.000 -284.84%
2021 -29.320.000 47.84%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Kindred Biosciences, Inc. Gross Profit
Year Gross Profit Growth
2012 0
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 1.642.000 100%
2019 3.669.000 55.25%
2020 37.538.000 90.23%
2021 11.592.000 -223.83%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Kindred Biosciences, Inc. Net Profit
Year Net Profit Growth
2012 -120.000
2013 -4.213.424 97.15%
2014 -27.139.000 84.47%
2015 -27.130.000 -0.03%
2016 -22.499.000 -20.58%
2017 -30.879.000 27.14%
2018 -49.690.000 37.86%
2019 -61.389.000 19.06%
2020 -23.624.000 -159.86%
2021 -38.848.000 39.19%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Kindred Biosciences, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2012 0
2013 -1 100%
2014 -1 0%
2015 -1 0%
2016 -1 0%
2017 -1 0%
2018 -2 0%
2019 -2 0%
2020 -1 0%
2021 -1 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Kindred Biosciences, Inc. Free Cashflow
Year Free Cashflow Growth
2012 -62.000
2013 -1.587.975 96.1%
2014 -22.374.000 92.9%
2015 -23.486.000 4.73%
2016 -19.733.000 -19.02%
2017 -27.798.000 29.01%
2018 -58.954.000 52.85%
2019 -64.770.000 8.98%
2020 -13.495.000 -379.96%
2021 -2.710.000 -397.97%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Kindred Biosciences, Inc. Operating Cashflow
Year Operating Cashflow Growth
2012 -62.000
2013 -1.573.152 96.06%
2014 -21.934.000 92.83%
2015 -22.757.000 3.62%
2016 -18.781.000 -21.17%
2017 -21.878.000 14.16%
2018 -45.035.000 51.42%
2019 -56.342.000 20.07%
2020 -9.857.000 -471.59%
2021 -2.645.000 -272.67%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Kindred Biosciences, Inc. Capital Expenditure
Year Capital Expenditure Growth
2012 0
2013 14.823 100%
2014 440.000 96.63%
2015 729.000 39.64%
2016 952.000 23.42%
2017 5.920.000 83.92%
2018 13.919.000 57.47%
2019 8.428.000 -65.15%
2020 3.638.000 -131.67%
2021 65.000 -5496.92%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Kindred Biosciences, Inc. Equity
Year Equity Growth
2012 -119.311
2013 63.278.474 100.19%
2014 99.024.000 36.1%
2015 76.371.000 -29.66%
2016 57.680.000 -32.4%
2017 84.680.000 31.88%
2018 91.207.000 7.16%
2019 81.921.000 -11.34%
2020 67.482.000 -21.4%
2021 79.769.000 15.4%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Kindred Biosciences, Inc. Assets
Year Assets Growth
2012 938.020
2013 65.488.070 98.57%
2014 101.920.000 35.75%
2015 79.619.000 -28.01%
2016 61.576.000 -29.3%
2017 90.822.000 32.2%
2018 106.482.000 14.71%
2019 114.024.000 6.61%
2020 95.814.000 -19.01%
2021 108.872.000 11.99%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Kindred Biosciences, Inc. Liabilities
Year Liabilities Growth
2012 1.057.331
2013 2.209.596 52.15%
2014 2.896.000 23.7%
2015 3.248.000 10.84%
2016 3.896.000 16.63%
2017 6.142.000 36.57%
2018 15.275.000 59.79%
2019 32.103.000 52.42%
2020 28.332.000 -13.31%
2021 29.103.000 2.65%

Kindred Biosciences, Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
1.07
Net Income per Share
-0.6
Price to Earning Ratio
-15.38x
Price To Sales Ratio
0x
POCF Ratio
-36.87
PFCF Ratio
0
Price to Book Ratio
5.39
EV to Sales
0.21
EV Over EBITDA
-0.58
EV to Operating CashFlow
-0.89
EV to FreeCashFlow
-0.65
Earnings Yield
-0.07
FreeCashFlow Yield
0
Market Cap
0,00 Bil.
Enterprise Value
0,01 Bil.
Graham Number
4.82
Graham NetNet
0.78

Income Statement Metrics

Net Income per Share
-0.6
Income Quality
0.45
ROE
-0.32
Return On Assets
-0.25
Return On Capital Employed
-0.22
Net Income per EBT
1.08
EBT Per Ebit
1.09
Ebit per Revenue
-0.47
Effective Tax Rate
-0.08

Margins

Sales, General, & Administrative to Revenue
0.52
Research & Developement to Revenue
0.74
Stock Based Compensation to Revenue
0.18
Gross Profit Margin
0.89
Operating Profit Margin
-0.47
Pretax Profit Margin
-0.52
Net Profit Margin
-0.56

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.25
Free CashFlow per Share
-0.34
Capex to Operating CashFlow
0.37
Capex to Revenue
-0.09
Capex to Depreciation
-0.78
Return on Invested Capital
-0.25
Return on Tangible Assets
-0.25
Days Sales Outstanding
5.4
Days Payables Outstanding
11.44
Days of Inventory on Hand
16.33
Receivables Turnover
67.57
Payables Turnover
31.9
Inventory Turnover
22.35
Capex per Share
-0.09

Balance Sheet

Cash per Share
1,49
Book Value per Share
1,72
Tangible Book Value per Share
1.72
Shareholders Equity per Share
1.72
Interest Debt per Share
0.57
Debt to Equity
0.3
Debt to Assets
0.21
Net Debt to EBITDA
-0.58
Current Ratio
9.08
Tangible Asset Value
0,07 Bil.
Net Current Asset Value
0,03 Bil.
Invested Capital
0.3
Working Capital
0,06 Bil.
Intangibles to Total Assets
0
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
2212500
Debt to Market Cap
0

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Kindred Biosciences, Inc. Dividends
Year Dividends Growth

Kindred Biosciences, Inc. Profile

About Kindred Biosciences, Inc.

Kindred Biosciences, Inc., a biopharmaceutical company, is developing biologics that focus on the lives of pets. The company has a pipeline of novel biologics in development across various therapeutic classes and intellectual property portfolio. Its programs under development include interleukin-31 and interleukin-4R for canine atopic dermatitis; KIND-030 for parvovirus in dogs; KIND-510a for the control of non-regenerative anemia in cats; anti-TNF antibody for inflammatory bowel disease in dogs; and other biologics candidates. The company was founded in 2012 and is headquartered in Burlingame, California.

CEO
Dr. Richard Chin
Employee
63
Address
1555 Bayshore Hwy Ste 200
Burlingame, 94010

Kindred Biosciences, Inc. Executives & BODs

Kindred Biosciences, Inc. Executives & BODs
# Name Age

Kindred Biosciences, Inc. Competitors